TCM
Tang Capital Management Portfolio holdings
AUM
$1.98B
This Quarter Return
-5.03%
1 Year Return
+21.62%
3 Year Return
+290.69%
5 Year Return
+284.46%
10 Year Return
+928.34%
AUM
$1.81B
AUM Growth
+$1.81B
(+20%)
Cap. Flow
+$415M
Cap. Flow
% of AUM
22.93%
Top 10 Holdings %
Top 10 Hldgs %
39.2%
Holding
208
New
25
Increased
77
Reduced
32
Closed
6
Top Buys
| 1 |
Dynavax Technologies
DVAX
|
$50.6M |
| 2 |
Galapagos
GLPG
|
$45.2M |
| 3 |
Kiniksa Pharmaceuticals
KNSA
|
$33.1M |
| 4 |
Spyre Therapeutics
SYRE
|
$33.1M |
| 5 |
SLRN
ACELYRIN
SLRN
|
$24.3M |
Top Sells
Sector Composition
| 1 | Healthcare | 94.79% |
| 2 | Technology | 1.25% |
| 3 | Communication Services | 1.23% |
| 4 | Consumer Discretionary | 0.99% |
| 5 | Financials | 0.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Tarsus Pharmaceuticals
TARS
$2.47B
| $126M | 6.98% | 2,454,797 +200,000 | +9% | +$10.3M |
|
|
2
Galapagos
GLPG
$2.07B
| $99.5M | 5.51% | 3,961,797 +1,800,597 | +83% | +$45.2M |
|
3
Aurinia Pharmaceuticals
AUPH
$1.58B
| $80.6M | 4.46% | 10,029,500 +1,600,000 | +19% | +$12.9M |
|
|
4
Dynavax Technologies
DVAX
$1.19B
| $74.6M | 4.13% | 5,750,000 +3,900,000 | +211% | +$50.6M |
|
5
Evolus
EOLS
$494M
| $60.1M | 3.33% | 4,997,399 | – | – |
|
6
KalVista Pharmaceuticals
KALV
$678M
| $57M | 3.16% | 4,941,798 +47,951 | +1% | +$553K |
|
7
Immunocore
IMCR
$1.62B
| $56.8M | 3.14% | 1,915,708 +360,108 | +23% | +$10.7M |
|
8
Mirum Pharmaceuticals
MIRM
$3.71B
| $55.7M | 3.08% | 1,237,107 | – | – |
|
9
PTC Therapeutics
PTCT
$3.92B
| $51M | 2.82% | 1,000,000 +300,000 | +43% | +$15.3M |
|
|
10
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $47.1M | 2.6% | 2,118,579 +1,489,970 | +237% | +$33.1M |
|
11
Viridian Therapeutics
VRDN
$1.5B
| $37.6M | 2.08% | 2,792,925 +300,000 | +12% | +$4.04M |
|
|
12
Spyre Therapeutics
SYRE
$996M
| $33.1M | 1.83% | +2,050,000 | New | +$33.1M |
|
|
ITCI
13
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $29M | 1.61% | 220,000 -80,000 | -27% | -$10.6M |
|
14
AnaptysBio
ANAB
$569M
| $28.7M | 1.59% | 1,545,153 +214,274 | +16% | +$3.98M |
|
15
Replimune Group
REPL
$422M
| $28.3M | 1.56% | 2,900,000 +200,000 | +7% | +$1.95M |
|
16
Legend Biotech
LEGN
$6.41B
| $28.2M | 1.56% | 830,000 +380,000 | +84% | +$12.9M |
|
17
Acadia Pharmaceuticals
ACAD
$4.38B
| $24.9M | 1.38% | 1,500,000 | – | – |
|
18
BioNTech
BNTX
$24B
| $24.6M | 1.36% | 270,000 | – | – |
|
|
SLRN
19
DELISTED
ACELYRIN
SLRN
| $24.3M | 1.34% | +9,818,115 | New | +$24.3M |
|
20
Jazz Pharmaceuticals
JAZZ
$7.75B
| $23.6M | 1.31% | 190,000 +50,000 | +36% | +$6.21M |
|
21
ANI Pharmaceuticals
ANIP
$2.03B
| $21.3M | 1.18% | 317,500 | – | – |
|
22
Relay Therapeutics
RLAY
$619M
| $21.1M | 1.17% | 8,068,058 | – | – |
|
23
Compass Therapeutics
CMPX
$483M
| $21M | 1.16% | 11,052,632 +5,152,632 | +87% | +$9.79M |
|
24
ADMA Biologics
ADMA
$4.12B
| $20.8M | 1.15% | 1,050,000 +500,000 | +91% | +$9.92M |
|
|
LENZ
25
LENZ Therapeutics
LENZ
$1.1B
| $19.7M | 1.09% | 766,940 | – | – |
|